# Profusa, Inc. (PFSA) — spac/extension [announced]
Source: sec.gov · situation sit_b066a22d173603708a7e · public 9636159227210715004 · retrieved 2026-08-22T12:22:24.375Z

## Overview
Profusa, Inc. is a digital health company developing tissue-integrated biosensor technologies to detect and continuously transmit medical-grade data for personal and medical use.

Profusa, Inc. has signed an Option Agreement providing the right (but not obligation) to acquire G3 Vision Labs, Inc. and its subsidiaries, subject to satisfaction of certain conditions. Upon exercise, the combined company will operate as a public diagnostics company with CLIA-certified national laboratories serving addiction treatment, pain management, and behavioral health providers. To date, debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements, of which $4,570,298 was exchanged for 4,271.298 shares of Series A Convertible Preferred Stock. G3's audited 2024 and 2025 financial statements are expected by mid-September 2026.

## Terms
- Counterparty: G3 Vision Labs, Inc. · Deal value: $10.7M · Consideration: mixed

## Key dates
- Announced 2026-08-20

## Timeline
- 2026-08-20 · 8-K (0001213900-26-091905): 8-K - Profusa, Inc. — *Profusa, Inc. is a digital health company developing tissue-integrated biosensor technologies to detect and continuously transmit medical-grade data for personal and medical use.* Profusa, Inc. has signed an Option Agreement providing the right (but not obligation) to acquire G3 Vision Labs, Inc. and its subsidiaries, subject to satisfaction of certain conditions. Upon exercise, the combined company will operate as a public diagnostics company with CLIA-certified national laboratories serving addiction treatment, pain management, and behavioral health providers. To date, debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements, of which $4,570,298 was exchanged for 4,271.298 shares of Series A Convertible Preferred Stock. G3's audited 2024 and 2025 financial statements are expected by mid-September 2026.
  https://www.sec.gov/Archives/edgar/data/1859807/0001213900-26-091905.txt

## Citations
- 0001213900-26-091905 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000121390026091905